"Dioxoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D004149
|
| MeSH Number(s) |
D03.383.246
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dioxoles".
Below are MeSH descriptors whose meaning is more specific than "Dioxoles".
This graph shows the total number of publications written about "Dioxoles" by people in this website by year, and whether "Dioxoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 4 | 4 | 8 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dioxoles" by people in Profiles.
-
Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2. J Mol Graph Model. 2020 12; 101:107717.
-
Cytotoxicity of fagaramide derivative and canthin-6-one from Zanthoxylum (Rutaceae) species against multidrug resistant leukemia cells. Nat Prod Res. 2021 Feb; 35(4):579-586.
-
Furoquinolines and dihydrooxazole alkaloids with cytotoxic activity from the stem bark of Araliopsis soyauxii. Fitoterapia. 2019 Mar; 133:193-199.
-
A comprehensive review on the anti-cancer properties and mechanisms of action of sesamin, a lignan in sesame seeds (Sesamum indicum). Eur J Pharmacol. 2017 Nov 15; 815:512-521.
-
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol. 2017 Oct 10; 35(29):3347-3353.
-
Novel Gomisin B analogues as potential cytotoxic agents: Design, synthesis, biological evaluation and docking studies. Eur J Med Chem. 2017 Oct 20; 139:441-453.
-
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017 Aug 22; 117(5):628-638.
-
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. Int J Gynecol Cancer. 2017 07; 27(6):1141-1148.
-
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 06; 18(6):812-822.
-
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. Support Care Cancer. 2017 06; 25(6):1743-1748.